MCM
NTLA icon

Moore Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Moore Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-111,726
Closed -$15M – 827
2021
Q3 		$15M Buy
111,726
+50,833
+83% +$7.7M 0.23% 89
2021
Q2 		$9.86M Sell
60,893
-124,541
-67% -$9.7M 0.14% 134
2021
Q1 		$14.9M Buy
185,434
+138,012
+291% +$9.26M 0.19% 96
2020
Q4 		$2.58M Buy
+47,422
New +$1.72M 0.03% 325

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Moore Capital Management's NTLA Position: Q4 2021 in Review

Moore Capital Management sold out of Intellia Therapeutics (NTLA) in Q4 2021, closing a stake of 111,726 shares — an estimated $15M sold.

Moore Capital Management first reported a position in NTLA in Q4 2020 and held it in 4 quarters. The position peaked at $15M in Q3 2021. 371 funds tracked by Wall St. Rank hold NTLA as of Q4 2021.

  • Moore Capital Management reported no remaining Intellia Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Moore Capital Management sold 111,726 Intellia Therapeutics shares in Q4 2021, an estimated $15M.
  • Moore Capital Management first reported a position in Intellia Therapeutics in Q4 2020 and held it in 4 quarters.
  • Moore Capital Management's Intellia Therapeutics position peaked at $15M in Q3 2021.
  • 371 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2021.

Based on Moore Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.